Creating new treatments to enhance cancer immunotherapy effectiveness
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
This study is looking at new drugs that target a protein called RIPK1 to help boost the immune system's ability to fight cancer, especially for patients who haven't had success with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11072471 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drugs that target RIPK1, a protein involved in regulating immune responses and cell death in cancer. By understanding how RIPK1 affects the effectiveness of cancer immunotherapies, the researchers aim to improve treatment outcomes for patients who currently do not respond to existing therapies. The approach involves both genetic studies and drug development to create first-in-class RIPK1 degraders that could enhance the immune system's ability to fight cancer. Patients may benefit from these advancements through improved responses to immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer who have not responded to existing immunotherapy treatments.
Not a fit: Patients with early-stage cancer or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients who are currently non-responders to immunotherapy.
How similar studies have performed: Other studies have shown promising results in targeting RIPK1 to enhance cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Jin — Baylor College of Medicine
- Study coordinator: Wang, Jin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.